Anthony J. Olszanski, RPh, MD, and Caroline Robert, MD, PhD, on Results From the KEYNOTE-001 Melanoma Trial
2016 ASCO Annual Meeting
Anthony J. Olszanski, RPh, MD, of Fox Chase Cancer Center, and Caroline Robert, MD, PhD, of Gustave Roussy and Paris-Sud University, discuss study findings on pembrolizumab and the overall survival benefit for patients with advanced disease (Abstract 9503).
John D. Hainsworth, MD, of the Sarah Cannon Research Institute, discusses early findings from this umbrella basket study on targeted treatment, outside of current drug indications, for different types of advanced solid tumors (Abstract LBA11511).
Hope S. Rugo, MD, of the University of California, San Francisco, discusses phase III study results on a new possible alternative to trastuzumab for HER2-positive metastatic breast cancer: the biosimilar known as Myl-1401O (Abstract LBA503).
The
Lisa A. Carey, MD, of the University of North Carolina, and Julie Gralow, MD, of the University of Washington, discuss the most important data presented this year on treating breast malignancies (Abstracts LBA1, 500, and 507).
Lee S. Schwartzberg, MD, of The West Clinic, reports on progress of the now year-old ACCC initiative to speed adoption of immunotherapeutics in community practices.
Rakesh Chopra, MD, of the Artemis Health Institute, and Mary Gospodarowicz, MD, of Princess Margaret Hospital, discuss oncology from an international point of view.